Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.5 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 0.5 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.